fda and tirzepatide shortage What is the latest update on the Compounded ban Lilly's Tirzepatide No Longer on

GHK-Cu (Copper Peptide) Overview: GHK-Cu is a copper-binding peptide with regenerative, anti-inflammatory, and antioxidant properties

Regulators approve medications for particular uses, populations, and dosing schedules, and those labels become the default playbook for clinical care

However, corticosteroids are not the preferred treatment option for long-term treatment of UC, as long-term use may cause a range of side effects, including immunosuppression, increased blood sugar, and weight gain

Simultaneous use can increase the risk of common side effects and serious complications, including thyroid cancer, pancreatitis, and gallbladder issues